Table 1.
Characteristics of Primary Breast Cancer Patientsa.
| Total | Control | VA | Ctx | Ctx + VA | |
|---|---|---|---|---|---|
| Number of patients, n (%) | 319 (100) | 159 (100) | 73 (100) | 31 (100) | 56 (100) |
| Age, years, median (IQR) | 59 (50-69) | 63 (53-71) | 56 (50-64) | 49 (43-56) | 57 (50-67) |
| BMI, median (IQR) | 25 (22-28) | 25 (22-28) | 23 (22-26) | 25 (23-28) | 24 (22-29) |
| Underweight (BMI <18.5) | 6 (1.9) | 1 (0.6) | 2 (2.7) | 2 (6.3) | 1 (1.8) |
| Normal (18.5 ⩽ BMI < 25) | 169 (53.0) | 79 (49.7) | 44 (60.3) | 13 (41.9) | 33 (58.9) |
| Overweight (25 ⩽ BMI < 30) | 97 (30.4) | 52 (32.7) | 20 (27.4) | 12 (38.7) | 13 (23.2) |
| Obese (BMI ⩾30) | 44 (13.8) | 24 (15.1) | 7 (9.6) | 4 (12.9) | 9 (16.1) |
| NA | 3 (0.9) | 3 (0.9) | 0 | 0 | 0 |
| UICC stages, n (%) | |||||
| 0 | 29 (9.1) | 17 (10.7) | 12 (16.4) | 0 | 0 |
| I | 155 (49.6) | 84 (52.8) | 40 (54.8) | 10 (32.3) | 21 (37.5) |
| II | 108 (33.9) | 53 (33.3) | 17 (23.3) | 13 (41.9) | 25 (44.6) |
| III | 25 (7.8) | 4 (2.5) | 3 (4.1) | 8 (25.8) | 10 (17.9) |
| NA | 2 (0.7) | 1 (0.6) | 1 (1.4) | 0 | 0 |
| ICD-10, n (%) | |||||
| C50.9 (Mammakarzinom) | 288 (90.3) | 140 (88.1) | 61 (83.6) | 31 (100) | 56 (100) |
| D05.1 (DCIS) | 31 (9.7) | 19 (11.9) | 12 (16.4) | 0 | 0 |
| Hormonal status, n (%) | |||||
| Premenopausal | 86 (27.0) | 28 (17.6) | 25 (34.2) | 16 (51.6) | 17 (30.4) |
| Perimenopausal | 10 (3.1) | 5 (3.1) | 0 | 3 (9.7) | 2 (3.6) |
| Postmenopausal | 213 (66.8) | 119 (74.8) | 46 (63.0) | 11 (35.5) | 37 (66.1) |
| NA | 10 (3.1) | 7 (4.4) | 2 (2.7) | 1 (3.2) | 0 |
| Estrogen receptor, n (%) | |||||
| Positive | 271 (85.0) | 149 (93.7) | 68 (93.2) | 19 (61.3) | 35 (62.5) |
| Negative | 43 (13.5) | 8 (5.0) | 3 (4.1) | 12 (38.7) | 20 (35.7) |
| NA | 5 (1.6) | 2 (1.3) | 2 (2.7) | 0 | 1 (1.8) |
| Progesterone receptor, n (%) | |||||
| Positive | 259 (81.2) | 146 (91.8) | 60 (82.2) | 19 (61.3) | 34 (60.7) |
| Negative | 54 (16.9) | 10 (6.3) | 11 (15.1) | 12 (38.7) | 21 (37.5) |
| NA | 6 (1.9) | 3 (0.9) | 2 (2.7) | 0 | 1 (1.8) |
| Her 2, n (%) | |||||
| Positive | 44 (13.8) | 8 (5.0) | 4 (5.5) | 10 (32.3) | 22 (39.3) |
| Negative | 251 (78.7) | 137 (86.2) | 61 (83.6) | 21 (67.7) | 32 (57.1) |
| NA | 24 (7.5) | 14 (8.8) | 8 (11.0) | 0 | 2 (3.6) |
| Triple-negative status, n (%) | |||||
| Yes | 21 (6.6) | 3 (0.9) | 2 (2.7) | 7 (22.6) | 9 (16.1) |
| No | 291 (91.2) | 153 (96.2) | 69 (94.5) | 24 (77.4) | 45 (80.4) |
| NA | 7 (2.2) | 3 (0.9) | 2 (2.7) | 0 | 2 (3.6) |
| Interventions, n (%) | |||||
| Radiation | 251 (78.7) | 127 (79.9) | 52 (71.2) | 27 (87.0) | 45 (80.4) |
| Endocrine therapy | 209 (65.5) | 110 (69.2) | 51 (69.9) | 14 (45.2) | 34 (60.7) |
| Chemotherapy | 87 (27.3) | 0 | 0 | 31 (100) | 56 (100) |
| Immunotherapy | 29 (9.1) | 0 | 1 (1.4) | 7 (22.6) | 21 (37.5) |
| Mistletoe therapy | 129 (40.4) | 0 | 73 (100) | 0 | 56 (100) |
Abbreviations: VA, Viscum album L therapy; Ctx, chemotherapy; IQR, interquartile range; BMI, body mass index; UICC, Union for International Cancer Control; ICD-10, International Classification of Diseases, 10th Revision.
a
TNM staging according to the UICC.